ライフサイエンスコーパス: hereditary breast cancer

1 pective Study of Outcomes in Sporadic versus Hereditary breast cancer.

2 astases in sporadic breast cancer but not in hereditary breast cancer.

3 ity genetic disorder Fanconi anemia (FA) and hereditary breast cancer.

4 ffect its structure-function relationship in hereditary breast cancer.

5 A2, are responsible for the vast majority of hereditary breast cancer.

6 f the BRCA2 gene contribute significantly to hereditary breast cancer.

7 yet be found that explain some proportion of hereditary breast cancer.

8 moderate to high penetrant genes involved in hereditary breast cancer.

9 tions in BRCA genes are the leading cause of hereditary breast cancer.

10 tions (BRCA1(+/mut)) have increased risk for hereditary breast cancer.

11 Germline mutations in BRCA2 predispose to hereditary breast cancers.

12 btype in human sporadic and BRCA1-associated hereditary breast cancers.

13 oportion of non BRCA1-, non BRCA2-associated hereditary breast cancers.

14 le for a significant fraction of early-onset hereditary breast cancers.

15 st frequent mutation alleles predisposing to hereditary breast cancer among the Ashkenazim, and sugge

16 lial and stromal cells from 43 patients with hereditary breast cancer and 175 patients with sporadic

17 sible for approximately half of all cases of hereditary breast cancer and almost all cases of combine

18 nactivated by gross gene disruption in BRCA1 hereditary breast cancer and BRCA1-methylated sporadic b

19 some of which were previously identified in hereditary breast cancer and Fanconi anemia.

20 basal-like breast cancer but rarely in BRCA2 hereditary breast cancer and non-BRCA1-deficient sporadi

21 mbination with mutations in genes that cause hereditary breast cancer and ovarian cancer like BRCA1,

22 ent options in the management of early-stage hereditary breast cancer and should provide reassurance

23 methods are tested on data sets arising from hereditary breast cancer and small round blue-cell tumor

24 BRCA1 or BRCA2 in a sample of North American hereditary breast cancers and assess the evidence for ad

25 1 (BRCA1) is mutated in approximately 50% of hereditary breast cancers, and its expression is decreas

26 Many cases of hereditary breast cancer are due to mutations in either

27 nes later in life suggest that most cases of hereditary breast cancer are not related to cumulative h

28 When hereditary breast cancer cannot be ruled out, individual

29 ssion data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutatio

30 ient in other DSB repair pathways, including hereditary breast cancers defective in homologous recomb

31 Hereditary breast cancer due to mutations in BRCA1 and B

32 -like subtype, which include the majority of hereditary breast cancers due to mutations in the breast

33 We describe the proportion of hereditary breast cancer explained by BRCA1 or BRCA2 in

34 Finally, analysis of a small cohort of hereditary breast cancers failed to reveal any associati

35 the potential role of RRSO in BRCA-negative hereditary breast cancer families will also be discussed

36 Much of the published work on management of hereditary breast cancer focuses on women with known mut

37 The second hereditary breast cancer gene, BRCA2, was recently isola

38 chemosensitivity of tumors deficient in the hereditary breast cancer genes BRCA1 and BRCA2 (BRCA).

39 Predisposition to hereditary breast cancer has been attributed in part to

40 white individuals, but little is known about hereditary breast cancer in Asian populations.

41 ever, it is not yet clear what proportion of hereditary breast cancer is explained by BRCA1 and BRCA2

42 6174delT frameshift mutation in BRCA2 in an hereditary breast cancer kindred of Ashkenazi Jewish anc

43 An autosomal dominant pattern of hereditary breast cancer may be masked by small family s

44 Education about hereditary breast cancer may be needed among primary car

45 ve, perhaps allowing us to identify cases of hereditary breast cancer on the basis of gene-expression

46 factor important in meiosis, associated with hereditary breast cancer (p = 0.018) and likely represen

47 We found that 0 of 42 (0%) of these hereditary breast cancer patients had other germ-line p5

48 utations, identified in 189 Northern Finnish hereditary breast cancer patients in parallel sequencing

49 48 pancreatic tumors, and 10 non-BRCA1/BRCA2 hereditary breast cancer patients.

50 e (13964GC) was identified in 3 of 42 (7.1%) hereditary breast cancer patients.

51 tions, although they were found in the other hereditary breast cancer patients.

52 pective Study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) study (n=315, 108 events

53 pective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH).

54 Hereditary breast cancer, primarily linked to pathogenic

55 ks, which is shared with two other high-risk hereditary breast cancer suppressors, BRCA2 and PALB2.

56 The hereditary breast cancer susceptibility gene, BRCA2, is

57 The protein products of the hereditary breast cancer susceptibility genes, BRCA1 and

58 The two major hereditary breast cancer susceptibility genes, BRCA1 and

59 Clearly, hereditary breast cancer susceptibility is a complex phe

60 tion carrier, family history consistent with hereditary breast cancer syndrome and estimated personal

61 We studied women at high risk of hereditary breast cancer syndromes who underwent testing

62 y beneficial in other syndromes, such as the hereditary breast cancer syndromes, hereditary nonpolypo

63 have also been identified and contribute to hereditary breast cancer syndromes.

64 1 and BRCA2 probably explain the majority of hereditary breast cancer that exists in the North Americ

65 also called BACH1/BRIP1 was first linked to hereditary breast cancer through its direct interaction

66 y engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to sev

67 tellite locus (2p25.1) in stromal cells from hereditary breast cancers was associated with mutated TP

68 tations of which contribute significantly to hereditary breast cancer, was not identified in the exis

69 e BRCA1 tumor suppressor that predisposes to hereditary breast cancer when lost.

70 of the clinical or pathological features of hereditary breast cancer with somatic TP53 mutations.

71 mutations in PALB2 are an important cause of hereditary breast cancer, with respect both to the frequ